


Vanderbilt collaboration yields promising compound to treat arrhythmia

February 22 2019, by Heidi Hall



Credit: CC0 Public Domain

A collaboration between Vanderbilt University professors of chemistry and medicine yielded a promising compound to treat arrhythmia from an unlikely place: the fungal natural product verticilide.

Jeffrey Johnston, Stevenson Professor of Chemistry, said the natural



product isn't active except in insects, but the synthetic mirror-image version – or enantiomer – created in his lab is potently active in mammals against <u>ryanodine receptor</u> type 2, whose dysfunction can cause irregular heartbeats. Currently, many patients who suffer from arrhythmia are dependent on <u>implantable cardioverter-defibrillators</u> to keep their hearts working properly.

Johnston worked with Bjorn Knollmann, director of the Vanderbilt Center for Arrhythmia Research and Therapeutics, to show the synthetic compound inhibited calcium leak from ryanodine receptors, thus preventing arrhythmia.

In addition to establishing potency, the team's tests on cells and, later, mice showed that even high doses of the unnatural version caused no ill effects.

Their work appeared Feb. 21 in the *Proceedings of the National Academy of Science* in a paper titled "Unnatural verticilide <u>enantiomer</u> inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic."

The next steps will be establishing pharmacological properties, and, ultimately, develop a drug that could address the underlying problem and reduce the need for defibrillator implantations.

More information: Suzanne M. Batiste et al. Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic, *Proceedings of the National Academy of Sciences* (2019). DOI: 10.1073/pnas.1816685116

Provided by Vanderbilt University



Citation: Vanderbilt collaboration yields promising compound to treat arrhythmia (2019, February 22) retrieved 19 April 2024 from https://medicalxpress.com/news/2019-02-vanderbilt-collaboration-yields-compound-arrhythmia.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.